search
Back to results

Clinical Trial to Evaluate the Efficacy of Intracavernosal Infusion of PRP vs PPP for the Erectile Dysfunction. (PRePED)

Primary Purpose

Erectile Dysfunction

Status
Unknown status
Phase
Phase 2
Locations
Spain
Study Type
Interventional
Intervention
PRP
PPP
Sponsored by
Puerta de Hierro University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Erectile Dysfunction focused on measuring Platelet Rich Plasma, Platelet Poor Plasma

Eligibility Criteria

40 Years - 75 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed an ethics committee-reviewed and approved informed consent form.
  • Subjects must meet all inclusion criteria to be eligible for study enrollment.
  • Men between 40 and 75 years old, with a relationship of more than 6 months of duration.
  • Erectile dysfunction for at least 6 months with an IIEF-EF (while using the higher tolerated dose of PDE5-Is) between 5 and 16 points, inclusive.
  • Erectile dysfunction of vascular origin. In case of clinical doubt or incongruence, a Nocturnal Penile Tumescence and Rigidity Test (NPTR) will be performed. In this case, criteria inclusion is having no event in the night with a penile rigidity (tip) of ≥70% during ≥5min.
  • Subjects agree to attempt vaginal intercourse at least 4 times every month after the end of the treatment and agree to document the outcome using the Sexual Encounter Profile (SEP) and the Erection Hardness Score (EHS).
  • Commitment not to use other treatment for ED during the study (herbal, topical, intraurethral, intracavernosal, etc.).
  • Commitment to completing the rest of the questionnaires and other measurement instruments during the study phase.
  • Willingness and ability to comply with study procedures, other measurements instruments and visit schedules and able to follow oral and written instructions.

Exclusion Criteria:

  • Documented psychogenic erectile dysfunction (with NPTR test: at least one event in the night with a penile rigidity (tip) of ≥70% during ≥5min).
  • Erectile dysfunction of neurogenic origin (radical prostatectomy, pelvic surgery, spinal cord injury, multiple sclerosis, diabetes mellitus is not included unless documented diabetic neuropathy).
  • Some other current sexual dysfunction (premature ejaculation, etc.).
  • Prior implant of penile prosthesis or other penile surgeries different to circumcision, frenuloplasty or condyloma removal.
  • Previous history of penile fracture, Peyronie's disease or priapism.
  • History of radical prostatic or bladder surgery (radical cystectomy or prostatectomy).
  • Previous radiation to pelvis.
  • History of symptomatic hypogonadism (testosterone level <346ng/dl) not treated. If treated hypogonadism, testosterone levels non-stable for at least 3 months.
  • Major hematologic, renal, or hepatic abnormalities.
  • Severe decompensated cardiac and vascular insufficiency, or critical coronary heart disease.
  • Poorly controlled hypertension or diabetes mellitus (HbA1c >12%).
  • Recent (within previous six months of the inclusion) stroke or myocardial infarction.
  • Active peptic ulcer disease.
  • Neoplasm of any origin in active treatment or active progression.
  • History of psychiatric pathology (depressive syndrome, schizophrenia, bipolar disorder).
  • History of alcohol abuse (More than 7 alcohol drink units a week or more than 3 per occasion) or drug abuse (any drug consumption different to alcohol or tobacco, used more than three times per month).
  • Treatment with oral anticoagulants (dicoumarin or by-products) or antiandrogens.
  • Active treatment as nitric oxide (NO) donor drugs.
  • Prior positive serology to HBsAg, HCV (by genomic test), HIV-1/2, syphilis.
  • Thrombopenia less than 100 x 109 / L.
  • Anemia (Hemoglobin <13 g/dl).
  • Poor venous access or any other circumstance that preclude an apheresis procedure.
  • Lack of sexual practices in recent months (less than 4 attempts in the last three months).
  • Lack of commitment on the part of the patient to attend the tests requested.

Sites / Locations

  • Puerta de Hierro University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Treatment Arm

Control Arm

Arm Description

Intracavernosal infusion of Platelet Rich Plasma

Intracavernosal infusion of Platelet Poor Plasma

Outcomes

Primary Outcome Measures

Difference of increments between PRP and PPP treatment assessed by IIEF scale
Difference of increments between both treatment groups assesed by International Index Erectile Function (IIEF) scale (referred to the investigator's study as mean PRP V9(PT)IIEF-EF - V3IIEF-EF vs mean PPP V9(PT)IIEF-EF - V3IIEF-EF) after 4 weeks of the end of the treatment.

Secondary Outcome Measures

Incidence of adverse events related with the use of PRP/PPP
Incidence of infusion related Adverse Events (AEs) and cumulative of incidence of Serious Adverse Events (SAEs) during the clinical trial.
Synergic efficcacy of PRP and PDE5 inhibitors
Assessment of the synergic efficacy of PRP treatment on the therapeutic response to oral administration of PDE5 inhibitors by the IIEF.
Concentration of cytokines and growth factors in the PRP and PPP
Concentration of cytokines and growth factors concentration in the PRP and PPP of each patient and their relationship with the clinical response to PRP assessed by IIEF.

Full Information

First Posted
July 16, 2020
Last Updated
August 4, 2020
Sponsor
Puerta de Hierro University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04502875
Brief Title
Clinical Trial to Evaluate the Efficacy of Intracavernosal Infusion of PRP vs PPP for the Erectile Dysfunction.
Acronym
PRePED
Official Title
A Randomized, Double-blind Controlled Trial to Evaluate the Efficacy of Intracavernosal Infusion of Platelet Rich Plasma Against Platelet Poor Plasma in the Treatment of Vasculogenic Erectile Dysfunction.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2020
Overall Recruitment Status
Unknown status
Study Start Date
February 10, 2020 (Actual)
Primary Completion Date
February 28, 2022 (Anticipated)
Study Completion Date
August 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Puerta de Hierro University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Randomized, double-blind clinical trial to evaluate efficacy, feasibility and safety with two groups in a 1:1 ratio; where the control group corresponds to patients who will receive Platelet Poor plasma and an experimental group where patients will receive Platelet Rich Plasma, both collected by apheresis.
Detailed Description
Patients treated in the urology department of the Hospital Universitario Puerta de Hierro Majadahonda, are eligible and will be offered the participation in this clinical trial. The target populations are patients who presented erectile dysfunction for at least 6 months with an IIEF-EF between 5 and 16 points. They will be pre-screened for eligibility. The patient must complete the informed consent form (ICF) process and sign and date the informed consent form prior to participation in this study, including completion of any non-standard-of- care procedures required for this clinical Investigation. If the patient meets the inclusion criteria and additionally meet with the apheresis procedures, the patient wil be included in the study. The study include two phases. In the first phase, the patient will be randomized to PPP or PPP. In the second phase, according with the score IIEF-EF (responder or non responder), the patient will receive PRP. With the responders patients, an open phase with PDE5-Is is initiated. The patient will use phosphodiesterase 5 inhibitors (PDE5-Is) at maximum tolerated doses according with the Summary Product of characteristics. With the no responders patients, there will be two options: If the non-responder patient was in treatment with PRP during the firs phase, the patient will continue with the procedures of visits 11a and 12a. If the non-responder patient was in treatment with PPP, the patient will start the second phase of treatment with PRP and will continue with the procedures of this treatment phase.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Erectile Dysfunction
Keywords
Platelet Rich Plasma, Platelet Poor Plasma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Randomized, double-blind clinical trial to evaluate efficacy, feasibility and safety with two groups in a 1:1 ratio; where the control group corresponds to patients who will receive PPP and an experimental group where patients will receive PRP, both collected by apheresis.
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
52 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment Arm
Arm Type
Experimental
Arm Description
Intracavernosal infusion of Platelet Rich Plasma
Arm Title
Control Arm
Arm Type
Active Comparator
Arm Description
Intracavernosal infusion of Platelet Poor Plasma
Intervention Type
Drug
Intervention Name(s)
PRP
Intervention Description
Platelet Rich Plasma (PRP) is an autologous blood component derivate from the own patient blood, with a high concentration in platelets. The liquid fraction obtained after the soft centrifugation of Whole Blood (WB) collected with anticoagulant, in a way that most of the red cells and leukocytes are sedimented and removed, but most of the platelets are kept in the supernatant plasma. The platelet concentration in PRP is not well defined.
Intervention Type
Drug
Intervention Name(s)
PPP
Intervention Description
PPP is the liquid fraction obtained after the hard centrifugation of WB collected with any anticoagulant. PPP does not contain cells. (Hematocrit lower than 1% and leukocytes below 1 x 109/L) x but contains WB proteins (including clotting factors), ions, microelements and water. PPP can be also being collected using an apheresis technique.
Primary Outcome Measure Information:
Title
Difference of increments between PRP and PPP treatment assessed by IIEF scale
Description
Difference of increments between both treatment groups assesed by International Index Erectile Function (IIEF) scale (referred to the investigator's study as mean PRP V9(PT)IIEF-EF - V3IIEF-EF vs mean PPP V9(PT)IIEF-EF - V3IIEF-EF) after 4 weeks of the end of the treatment.
Time Frame
28 weeks
Secondary Outcome Measure Information:
Title
Incidence of adverse events related with the use of PRP/PPP
Description
Incidence of infusion related Adverse Events (AEs) and cumulative of incidence of Serious Adverse Events (SAEs) during the clinical trial.
Time Frame
28 weeks
Title
Synergic efficcacy of PRP and PDE5 inhibitors
Description
Assessment of the synergic efficacy of PRP treatment on the therapeutic response to oral administration of PDE5 inhibitors by the IIEF.
Time Frame
28 weeks
Title
Concentration of cytokines and growth factors in the PRP and PPP
Description
Concentration of cytokines and growth factors concentration in the PRP and PPP of each patient and their relationship with the clinical response to PRP assessed by IIEF.
Time Frame
28 weeks

10. Eligibility

Sex
Male
Gender Based
Yes
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed an ethics committee-reviewed and approved informed consent form. Subjects must meet all inclusion criteria to be eligible for study enrollment. Men between 40 and 75 years old, with a relationship of more than 6 months of duration. Erectile dysfunction for at least 6 months with an IIEF-EF (while using the higher tolerated dose of PDE5-Is) between 5 and 16 points, inclusive. Erectile dysfunction of vascular origin. In case of clinical doubt or incongruence, a Nocturnal Penile Tumescence and Rigidity Test (NPTR) will be performed. In this case, criteria inclusion is having no event in the night with a penile rigidity (tip) of ≥70% during ≥5min. Subjects agree to attempt vaginal intercourse at least 4 times every month after the end of the treatment and agree to document the outcome using the Sexual Encounter Profile (SEP) and the Erection Hardness Score (EHS). Commitment not to use other treatment for ED during the study (herbal, topical, intraurethral, intracavernosal, etc.). Commitment to completing the rest of the questionnaires and other measurement instruments during the study phase. Willingness and ability to comply with study procedures, other measurements instruments and visit schedules and able to follow oral and written instructions. Exclusion Criteria: Documented psychogenic erectile dysfunction (with NPTR test: at least one event in the night with a penile rigidity (tip) of ≥70% during ≥5min). Erectile dysfunction of neurogenic origin (radical prostatectomy, pelvic surgery, spinal cord injury, multiple sclerosis, diabetes mellitus is not included unless documented diabetic neuropathy). Some other current sexual dysfunction (premature ejaculation, etc.). Prior implant of penile prosthesis or other penile surgeries different to circumcision, frenuloplasty or condyloma removal. Previous history of penile fracture, Peyronie's disease or priapism. History of radical prostatic or bladder surgery (radical cystectomy or prostatectomy). Previous radiation to pelvis. History of symptomatic hypogonadism (testosterone level <346ng/dl) not treated. If treated hypogonadism, testosterone levels non-stable for at least 3 months. Major hematologic, renal, or hepatic abnormalities. Severe decompensated cardiac and vascular insufficiency, or critical coronary heart disease. Poorly controlled hypertension or diabetes mellitus (HbA1c >12%). Recent (within previous six months of the inclusion) stroke or myocardial infarction. Active peptic ulcer disease. Neoplasm of any origin in active treatment or active progression. History of psychiatric pathology (depressive syndrome, schizophrenia, bipolar disorder). History of alcohol abuse (More than 7 alcohol drink units a week or more than 3 per occasion) or drug abuse (any drug consumption different to alcohol or tobacco, used more than three times per month). Treatment with oral anticoagulants (dicoumarin or by-products) or antiandrogens. Active treatment as nitric oxide (NO) donor drugs. Prior positive serology to HBsAg, HCV (by genomic test), HIV-1/2, syphilis. Thrombopenia less than 100 x 109 / L. Anemia (Hemoglobin <13 g/dl). Poor venous access or any other circumstance that preclude an apheresis procedure. Lack of sexual practices in recent months (less than 4 attempts in the last three months). Lack of commitment on the part of the patient to attend the tests requested.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Juan Ignacio Martínez-Salamanca, MD, PhD
Phone
+34 91 191 71 95
Email
jims@lyxurologia.com
First Name & Middle Initial & Last Name or Official Title & Degree
Gustavo Centeno, MD, PhD
Phone
91 191 6026
Email
gustavoadolfo.centeno@salud.madrid.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Juan Martinez-Salamanca, Md, PhD
Organizational Affiliation
Urologist
Official's Role
Principal Investigator
Facility Information:
Facility Name
Puerta de Hierro University Hospital
City
Majadahonda
State/Province
Madrid
ZIP/Postal Code
28222
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gustavo Centeno, MD
Phone
91 191 6026
Email
gustavoadolfo.centeno@salud.madrid.org

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Clinical Trial to Evaluate the Efficacy of Intracavernosal Infusion of PRP vs PPP for the Erectile Dysfunction.

We'll reach out to this number within 24 hrs